The sentiment of this editorial that resources are spent on phase 3 trials without clear promise laid out in a phase 2 setting, with case in point being further exploration of VEGF-inhibition in conjunction with EGFR-inhibition for NSCLC appearing to be fueled more by a bev obsession than data. | West, JAMA Oncol 2021


Popular Posts